{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:10:29Z","timestamp":1782997829419,"version":"3.54.5"},"reference-count":80,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21EY033934"],"award-info":[{"award-number":["R21EY033934"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA240339"],"award-info":[{"award-number":["R01CA240339"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY028996"],"award-info":[{"award-number":["R01EY028996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY031097"],"award-info":[{"award-number":["R01EY031097"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA138264"],"award-info":[{"award-number":["R01CA138264"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000104","name":"NASA","doi-asserted-by":"publisher","award":["20-20TSRAD-2-0007"],"award-info":[{"award-number":["20-20TSRAD-2-0007"]}],"id":[{"id":"10.13039\/100000104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010310","name":"E. Matilda Ziegler Foundation for the Blind","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010310","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019329","name":"Emerson Collective","doi-asserted-by":"publisher","award":["T32EY007143"],"award-info":[{"award-number":["T32EY007143"]}],"id":[{"id":"10.13039\/100019329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT942523C0005"],"award-info":[{"award-number":["HT942523C0005"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015597","name":"Siebel Scholars Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006315","name":"CureSearch for Children's Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymthe.2025.03.027","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T13:20:29Z","timestamp":1742995229000},"page":"3128-3146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bispecific receptor decoy proteins block ocular neovascularization via simultaneous blockade of vascular endothelial growth factor A and C"],"prefix":"10.1016","volume":"33","author":[{"given":"Paul R.","family":"Sargunas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ariail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lima e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jikui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Silva","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuseong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia C.","family":"McCue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Carson","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander S.","family":"Popel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-3732","authenticated-orcid":false,"given":"Jamie B.","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.027_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0161-6420(02)01839-0","article-title":"Vision loss: a public health problem?","volume":"110","author":"Saaddine","year":"2003","journal-title":"Ophthalmol"},{"key":"10.1016\/j.ymthe.2025.03.027_bib2","series-title":"Making Eye Health a Population Health Imperative: Vision for Tomorrow","author":"Welp","year":"2016"},{"key":"10.1016\/j.ymthe.2025.03.027_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular Neovascularization","volume":"91","author":"Campochiaro","year":"2013","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ymthe.2025.03.027_bib5","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1074\/jbc.270.13.7717","article-title":"Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor \u00b7 Placenta Growth Factor Heterodimer (\u2217)","volume":"270","author":"DiSalvo","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.027_bib6","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1074\/jbc.271.6.3154","article-title":"Heterodimers of Placenta Growth Factor\/Vascular Endothelial Growth Factor: endothelial activity, tumor cell expression, and high affinity binding to Flk-1\/KDR","volume":"271","author":"Cao","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.027_bib7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","article-title":"Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1","volume":"9","author":"Autiero","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib8","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1172\/JCI114322","article-title":"Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis","volume":"84","author":"Connolly","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.027_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.027_bib10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ymthe.2025.03.027_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1465-9921-12-17","article-title":"Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung","volume":"12","author":"Sands","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.ymthe.2025.03.027_bib13","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1523\/JNEUROSCI.1092-08.2008","article-title":"Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration","volume":"28","author":"Poesen","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.027_bib14","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.0813061106","article-title":"VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.027_bib15","first-page":"492","article-title":"Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation","volume":"17","author":"Zhong","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2025.03.027_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40123-022-00618-4","article-title":"Determination of Vascular Endothelial Growth Factor-B Concentrations in Aqueous Humor and Plasma of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Patients Before and After Anti-VEGF Therapy","volume":"12","author":"Zhou","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.027_bib17","first-page":"517","article-title":"Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic","volume":"76","author":"Ziche","year":"1997","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ymthe.2025.03.027_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2025.03.027_bib19","doi-asserted-by":"crossref","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","article-title":"Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR","volume":"269","author":"Park","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.027_bib20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/IAE.0000000000003428","article-title":"Three-year treatment outcomes of aflibercept versus ranibizumab for diabetic macular edema","volume":"42","author":"Gabrielle","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2025.03.027_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159125","article-title":"Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab","volume":"133","author":"Cao","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.027_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-021-01625-8","article-title":"Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years","volume":"36","author":"Talks","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.ymthe.2025.03.027_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bcp.2019.07.021","article-title":"Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF\/ERK pathway","volume":"168","author":"Lazzara","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/bjo.2006.113902","article-title":"Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions","volume":"91","author":"Lux","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib25","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmol"},{"key":"10.1016\/j.ymthe.2025.03.027_bib26","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","article-title":"Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study","volume":"122","author":"Kuroda","year":"2015","journal-title":"Ophthalmol"},{"key":"10.1016\/j.ymthe.2025.03.027_bib27","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1097\/IAE.0000000000001383","article-title":"REecurrence in patients with type 3 neovascularization (retinal aingiomatous proliferation) after intravitreal ranibizumab","volume":"37","author":"Kim","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2025.03.027_bib28","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","article-title":"Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept","volume":"257","author":"Hara","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00417-018-04232-8","article-title":"Durability of Every-8-week Aflibercept Maintenance Therapy in Treatment Experienced Neovascular Age-related Macular Degeneration","volume":"257","author":"Dans","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2013.12.004","article-title":"Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression","volume":"346","author":"Li","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2025.03.027_bib31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/neuonc\/noy103","article-title":"VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance","volume":"20","author":"Michaelsen","year":"2018","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-010-0480-6","article-title":"Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells","volume":"104","author":"Grau","year":"2011","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib33","doi-asserted-by":"crossref","first-page":"14389","DOI":"10.1073\/pnas.95.24.14389","article-title":"Vascular endothelial growth factor C induces angiogenesis in vivo","volume":"95","author":"Cao","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.027_bib34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0002-9440(10)65582-4","article-title":"Vascular Endothelial Growth Factor-C (VEGF-C\/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia","volume":"153","author":"Witzenbichler","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/84635","article-title":"VEGF-D promotes the metastatic spread of tumor cells via the lymphatics","volume":"7","author":"Stacker","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jcp.22708","article-title":"Regulation of VEGF expression in human retinal cells by cytokines: Implications for the role of inflammation in age-related macular degeneration","volume":"227","author":"Nagineni","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib37","first-page":"2327","article-title":"Plasma Levels of VEGF-C and Soluble VEGF Receptor-3 are Elevated in Neovascular AMD","volume":"58","author":"Teague","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.03.027_bib38","first-page":"123","article-title":"Mechanisms of evasion to antiangiogenic therapy in glioblastoma","volume":"57","author":"Rose","year":"2010","journal-title":"Clin. Neurosurg."},{"key":"10.1016\/j.ymthe.2025.03.027_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","article-title":"Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers","volume":"2","author":"Cabral","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.ymthe.2025.03.027_bib40","unstructured":"4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD | 4D Molecular Therapeutics https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-presents-positive-interim-data-randomized-phase-2-prism\/."},{"key":"10.1016\/j.ymthe.2025.03.027_bib41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","article-title":"A Randomized Controlled Trial of OPT-302, a VEGF-C\/D Inhibitor for Neovascular Age-Related Macular Degeneration","volume":"130","author":"Jackson","year":"2023","journal-title":"Ophthalmol"},{"key":"10.1016\/j.ymthe.2025.03.027_bib42","doi-asserted-by":"crossref","first-page":"10699","DOI":"10.1128\/JVI.74.22.10699-10706.2000","article-title":"Viral Vascular Endothelial Growth Factor Plays a Critical Role in Orf Virus Infection","volume":"74","author":"Savory","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib43","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1074\/jbc.M313237200","article-title":"The Crystal Structure of Placental Growth Factor in Complex with Domain 2 of Vascular Endothelial Growth Factor Receptor-1","volume":"279","author":"Christinger","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.027_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jmb.2006.03.002","article-title":"Crystal Structure of Human Vascular Endothelial Growth Factor-B: Identification of Amino Acids Important for Receptor Binding","volume":"359","author":"Iyer","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.027_bib46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2010.07.001","article-title":"Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage","volume":"18","author":"Koh","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.027_bib47","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nm0398-336","article-title":"Vascular endothelial growth factor is essential for corpus luteum angiogenesis","volume":"4","author":"Ferrara","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib48","first-page":"6253","article-title":"Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor","volume":"60","author":"Gerber","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.027_bib49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib50","first-page":"574","article-title":"Vascular Endothelial Growth Factor\/Vascular Permeability Factor Is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model","volume":"145","author":"Miller","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib51","first-page":"1334","article-title":"Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis","volume":"37","author":"Shima","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.03.027_bib52","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.ebiom.2015.09.042","article-title":"Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling","volume":"2","author":"Singh","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2025.03.027_bib53","article-title":"Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage","volume":"9","author":"Silva","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib54","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1172\/JCI74527","article-title":"Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature","volume":"124","author":"Shen","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.027_bib55","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.027_bib56","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2011-11-390922","article-title":"Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization","volume":"119","author":"Brozzo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.027_bib57","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib58","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1074\/jbc.M111.228130","article-title":"Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-\u03b1 in Retinopathy and Psoriasis","volume":"286","author":"Jung","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.027_bib59","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1158\/0008-5472.CAN-09-3488","article-title":"Suppression of Tumor Growth and Metastasis by Simultaneously Blocking Vascular Endothelial Growth Factor (VEGF)\u2013A and VEGF-C with a Receptor-Immunoglobulin Fusion Protein","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.027_bib60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","article-title":"Targeting VEGF in eye neovascularization: What\u2019s new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development","volume":"103","author":"Amadio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ymthe.2025.03.027_bib61","unstructured":"Best-selling pharmaceuticals of 2023: Metabolic drugs shine https:\/\/www.drugdiscoverytrends.com\/best-selling-pharmaceuticals-2023\/."},{"key":"10.1016\/j.ymthe.2025.03.027_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106078","article-title":"Anti-angiogenic collagen IV-derived peptide target engagement with \u03b1v\u03b23 and \u03b15\u03b21 in ocular neovascularization models","volume":"26","author":"Lima e Silva","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2025.03.027_bib63","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.3390\/ijms21145142","article-title":"Suppression of Ocular Vascular Inflammation through Peptide-Mediated Activation of Angiopoietin-Tie2 Signaling","volume":"21","author":"Mirando","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.027_bib64","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122043","article-title":"A collagen IV\u2013derived peptide disrupts \u03b15\u03b21 integrin and potentiates Ang2\/Tie2 signaling","volume":"4","author":"Mirando","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.027_bib65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.027_bib66","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib67","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1038\/s41467-018-05982-z","article-title":"PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.027_bib68","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1167\/iovs.02-1092","article-title":"Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal Neovascularization","volume":"44","author":"Rakic","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.03.027_bib69","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1167\/iovs.16-21283","article-title":"Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization","volume":"58","author":"Crespo-Garcia","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.03.027_bib70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.str.2016.12.012","article-title":"Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A","volume":"25","author":"Markovic-Mueller","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.ymthe.2025.03.027_bib71","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2005.12.013","article-title":"Prevalence of age-related macular degeneration in 4 racial\/ethnic groups in the multi-ethnic study of atherosclerosis","volume":"113","author":"Klein","year":"2006","journal-title":"Ophthalmol"},{"key":"10.1016\/j.ymthe.2025.03.027_bib72","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ymthe.2025.03.027_bib73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H","article-title":"Retinal and choroidal neovascularization","volume":"184","author":"Campochiaro","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2005.01.017","article-title":"Focus on lymphangiogenesis in tumor metastasis","volume":"7","author":"Achen","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.027_bib75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jcp.21494","article-title":"Tumor lymphangiogenesis and melanoma metastasis","volume":"216","author":"Rinderknecht","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ymthe.2025.03.027_bib76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3677","article-title":"Lymphangiogenesis and lymphatic vessel remodelling in cancer","volume":"14","author":"Stacker","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.027_bib77","first-page":"1786","article-title":"Vascular Endothelial Growth Factor C Promotes Tumor Lymphangiogenesis and Intralymphatic Tumor Growth","volume":"61","author":"Karpanen","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.027_bib78","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.2147\/IJN.S377371","article-title":"Poly(Beta-Amino Ester)s as High-Yield Transfection Reagents for Recombinant Protein Production","volume":"17","author":"Luly","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ymthe.2025.03.027_bib79","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ymthe.2025.03.027_bib80","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65753-7","article-title":"Targeted Disruption of the FGF2 Gene Does Not Prevent Choroidal Neovascularization in a Murine Model","volume":"153","author":"Tobe","year":"1998","journal-title":"Am. J. Pathol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:13:02Z","timestamp":1782958382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1525001625002011"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.027","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific receptor decoy proteins block ocular neovascularization via simultaneous blockade of vascular endothelial growth factor A and C","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}